Literature DB >> 33593689

Glucagon use by U.S. adults with type 1 and type 2 diabetes.

Peter A Kahn1, Shuling Liu2, Rozalina McCoy3, Robert A Gabbay4, Kasia Lipska5.   

Abstract

The American Diabetes Association recommends that all patients at risk for hypoglycemia be prescribed glucagon. Despite this recommendation, there is evidence that prescription rates are lower than expected for patients with type 1 and type 2 diabetes. This study investigated prescription patterns for glucagon among de-identified administrative claims from OptumLabs® Data Warehouse for prescriptions between January 1, 2014 and December 31, 2014 among pharmacologically treated type 1 and 2 diabetes patients. We find that glucagon was rarely filled by patients with type 1 and type 2 diabetes, including fewer than 5% of patients with prior hypoglycemia requiring emergency healthcare utilization. Among patients with type 1 diabetes, glucagon fills were unpredictable and not targeted to highest risk patients.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Adverse drug events; Glucagon; Hypoglycemia; Type 1 diabetes; Type 2 diabetes

Mesh:

Substances:

Year:  2021        PMID: 33593689      PMCID: PMC8054027          DOI: 10.1016/j.jdiacomp.2021.107882

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  5 in total

1.  GLUCAGON PRESCRIPTION PATTERNS IN PATIENTS WITH EITHER TYPE 1 OR 2 DIABETES WITH NEWLY PRESCRIBED INSULIN.

Authors:  Beth D Mitchell; Xuanyao He; Ian M Sturdy; Andrew P Cagle; Julie A Settles
Journal:  Endocr Pract       Date:  2015-10-20       Impact factor: 3.443

2.  The incidence and costs of hypoglycemia in type 2 diabetes.

Authors:  Brian J Quilliam; Jason C Simeone; A Burak Ozbay; Stephen J Kogut
Journal:  Am J Manag Care       Date:  2011-10       Impact factor: 2.229

3.  Intranasal glucagon as remedy for hypoglycemia. Studies in healthy subjects and type I diabetic patients.

Authors:  A E Pontiroli; A Calderara; E Pajetta; M Alberetto; G Pozza
Journal:  Diabetes Care       Date:  1989-10       Impact factor: 19.112

4.  Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.

Authors:  Antonio E Pontiroli; Elena Tagliabue
Journal:  Acta Diabetol       Date:  2020-02-06       Impact factor: 4.280

  5 in total
  2 in total

1.  Management and Outcomes of Severe Hypoglycemia Treated by Emergency Medical Services in the U.S. Upper Midwest.

Authors:  Lucas A Myers; Kristi M Swanson; Amy E Glasgow; Rozalina G McCoy
Journal:  Diabetes Care       Date:  2022-08-01       Impact factor: 17.152

2.  Trends in Out-of-Pocket Cost of Glucagon, 2010-2020.

Authors:  Margaret Zupa; Robert Feldman; Jing Luo
Journal:  JAMA Netw Open       Date:  2022-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.